Utilities Registry – Center for Health Decision Science

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Valuation

Population

Condition

Viewing 1 - 10 of 44 results

Title	Year(s) of data collection	Valuation Method	Country	Condition
Selection of autoimmune disease health state utilities (He A, Spelman T et al., J Neurol Neurosurg Psychiatry. 2023. doi:10.1136/jnnp-2022-330169)	2001 - 2020	EQ-5D-3L	Sweden	Multiple sclerosis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 690 adults with relapsing multiple sclerosis in a Swedish registry to examine the association between early treatment of multiple sclerosis and patient-reported outcomes
Title Selection of autoimmune disease health state utilities (Armuzzi A et al., BMC Gastroenterol. 2023. doi:10.1186/s12876-023-02640-7)	Year(s) of data collection 2020 - 2021	Valuation Method EQ-5D-5L	Country France, Germany, Italy, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Ulcerative colitis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics a point-in-time survey of 164 matched patients treated with tofacitinib
Title Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)	Year(s) of data collection 2018 - 2020	Valuation Method EQ-5D-5L	Country Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title Selection of autoimmune disease health state utilities (Mitsikostas DD et al., Adv Ther. 2023. doi:10.1007/s12325-022-02388-8)	Year(s) of data collection 2012 - 2016	Valuation Method EQ-5D-3L	Country Greece	Condition Multiple sclerosis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics A prospective observational study of 458 participants under treatment with fingolimod conducted by hospital-based and private practice neurologists
Title Selection of autoimmune disease health state utilities (Schreiber S et al., J Crohns Colitis. 2023. doi:10.1093/ecco-jcc/jjad018)	Year(s) of data collection 2017 - 2018	Valuation Method EQ-5D	Country Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea (Republic of), Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Ukraine, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Ulcerative colitis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics An RCT for filgotinib in 786 adults with moderately to severely active UC
Title Selection of autoimmune disease health state utilities (Chung MP et al., Rheumatology (Oxford). 2022. doi:10.1093/rheumatology/keab810)	Year(s) of data collection 2016 - 2020	Valuation Method SF-6D	Country United States of America	Condition Calcinosis in systemic sclerosis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 12 participants from a prospective, single-arm, open-label, dose-escalation trial
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2021	Valuation Method EQ-5D-5L, HUI3	Country Belgium, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 9000 participants in the general population norms study that included adult patients with gMG randomly assigned to treatment with efgartigimod or conventional therapy
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L, HUI3	Country Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 1299 participants (EQ-5D-5L) and 549 participants (HUI3) from MyRealWorld-MG study
Title Selection of COVID-19 health state utilities (Chakravarty R et al., Indian J Psychol Med. 2023. doi:10.1177/02537176221140557)	Year(s) of data collection 2021	Valuation Method EQ-5D-5L	Country India	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 80 COVID-19 patients treated with single infusion tocilizumab or no treatment
Title Selection of COVID-19 health state utilities (Huarcaya-Victoria J et al., Qual Life Res. 2023. doi:10.1007/s11136-022-03208-w)	Year(s) of data collection 2020	Valuation Method EQ-5D-5L	Country Peru	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics prospective sample of 119 hospitalized patients who survived COVID-19 at 3 and 13 months after discharge

Next results →